Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) EVP Sells 5,934 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) EVP Erik Phelps sold 5,934 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $67.57, for a total transaction of $400,960.38. Following the sale, the executive vice president now owns 214,662 shares in the company, valued at approximately $14,504,711.34. The trade was a 2.69 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Tempus AI Trading Up 6.1 %

TEM opened at $68.96 on Monday. The company’s 50 day moving average is $44.49 and its 200 day moving average is $49.16. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI, Inc. has a 12-month low of $22.89 and a 12-month high of $79.49.

Analyst Ratings Changes

TEM has been the topic of several analyst reports. Guggenheim began coverage on Tempus AI in a research report on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $56.00 price target on shares of Tempus AI in a report on Tuesday, January 14th. Wolfe Research started coverage on Tempus AI in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective on the stock. Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and boosted their target price for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Finally, Loop Capital dropped their price target on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a report on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, Tempus AI currently has an average rating of “Moderate Buy” and an average price target of $58.55.

Institutional Investors Weigh In On Tempus AI

A number of hedge funds have recently modified their holdings of the business. Millennium Management LLC bought a new position in Tempus AI in the 2nd quarter worth $8,067,000. The Manufacturers Life Insurance Company purchased a new stake in Tempus AI in the second quarter worth about $946,000. Carnegie Investment Counsel bought a new position in shares of Tempus AI in the third quarter worth about $7,936,000. Exchange Traded Concepts LLC purchased a new position in shares of Tempus AI during the 3rd quarter valued at about $3,458,000. Finally, Renaissance Capital LLC bought a new position in shares of Tempus AI during the 3rd quarter valued at approximately $633,000. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.